A carregar...
Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs
One of the most significant developments in medical oncology practice has been the approval of various antiangiogenic drugs for the treatment of a number of different malignancies. These drugs include bevacizumab (Avastin®), the anti-VEGF monoclonal antibody. Thus far, bevacizumab appears to induce...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Korean Cancer Association
2007
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2739367/ https://ncbi.nlm.nih.gov/pubmed/19746237 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2007.39.4.150 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|